This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

Concert Pharmaceuticals Crecimiento futuro

Future controles de criterios 2/6

Información clave

38.9%

Tasa de crecimiento de los beneficios

43.3%

Tasa de crecimiento del BPA

Crecimiento de los beneficios de Biotechs	31.6%
Tasa de crecimiento de los ingresos	54.9%
Rentabilidad financiera futura	n/a
Cobertura de analistas	Low
Última actualización	06 Mar 2023

Actualizaciones recientes sobre el crecimiento futuro

No hay actualizaciones

Recent updates

Previsiones de crecimiento de beneficios e ingresos

DB:73C - Estimaciones futuras de los analistas y datos financieros pasados (USD Millions)
Fecha	Ingresos	Beneficios	Flujo de caja libre	Flujo de caja operativo	Núm. de analistas medio
12/31/2025	96	-69	N/A	-86	2
12/31/2024	29	-129	N/A	-140	2
12/31/2023	18	-137	N/A	-78	3
12/31/2022	0	-122	N/A	N/A	3
9/30/2022	32	-127	-110	-110	N/A
6/30/2022	33	-125	-103	-102	N/A
3/31/2022	33	-95	-67	-67	N/A
12/31/2021	33	-80	-55	-55	N/A
9/30/2021	1	-66	-45	-45	N/A
6/30/2021	2	-59	-47	-47	N/A
3/31/2021	8	-77	-72	-72	N/A
12/31/2020	8	-75	-69	-69	N/A
9/30/2020	8	-73	-68	-68	N/A
6/30/2020	6	-71	-64	-63	N/A
3/31/2020	0	-77	-66	-65	N/A
12/31/2019	1	-78	-49	-49	N/A
9/30/2019	1	-79	-50	-49	N/A
6/30/2019	1	-79	-47	-45	N/A
3/31/2019	1	-73	-40	-37	N/A
12/31/2018	11	-56	-51	-48	N/A
9/30/2018	11	-41	-41	-39	N/A
6/30/2018	11	104	104	106	N/A
3/31/2018	11	104	104	105	N/A
12/31/2017	0	95	103	104	N/A
9/30/2017	0	89	98	99	N/A
6/30/2017	0	-50	-46	-45	N/A
3/31/2017	0	-50	-45	-44	N/A
12/31/2016	0	-51	-46	-45	N/A
9/30/2016	10	-38	-33	-33	N/A
6/30/2016	12	-35	N/A	-30	N/A
3/31/2016	15	19	N/A	20	N/A

Previsiones de crecimiento futuro de los analistas

Ingresos vs. Tasa de ahorro: 73C is forecast to remain unprofitable over the next 3 years.

Beneficios vs. Mercado: 73C is forecast to remain unprofitable over the next 3 years.

Beneficios de alto crecimiento: 73C is forecast to remain unprofitable over the next 3 years.

Ingresos vs. Mercado: 73C's revenue (54.9% per year) is forecast to grow faster than the German market (3.3% per year).

Ingresos de alto crecimiento: 73C's revenue (54.9% per year) is forecast to grow faster than 20% per year.

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

ROE futura: Insufficient data to determine if 73C's Return on Equity is forecast to be high in 3 years time

This company listing is no longer active

Concert Pharmaceuticals Crecimiento futuro

Future controles de criterios 2/6

Información clave

Actualizaciones recientes sobre el crecimiento futuro

Recent updates

Concert Pharmaceuticals, Inc. Maintains Deuruxolitinib Breakthrough Therapy Designation from FDA for the Treatment of Alopecia Areata

Concert Pharmaceuticals Announces Presentation of Deuruxolitinib Thrive-Aa1 Phase 3 Study Results in Alopecia Areata During World Congress for Hair Research

Insufficient new directors

Third quarter 2022 earnings released: US$0.58 loss per share (vs US$0.78 loss in 3Q 2021)

Concert Pharmaceuticals, Inc. to Report Q3, 2022 Results on Nov 07, 2022

Concert Pharmaceuticals Announces Presentation of CTP-543 THRIVE-AA1 Phase 3 Data in Alopecia Areata During Late Breaking Session at EADV Congress

Second quarter 2022 earnings released: US$0.59 loss per share (vs US$0.16 profit in 2Q 2021)

Concert Pharmaceuticals, Inc. Reports Positive Topline Results for Second CTP-543 Phase 3 Clinical Trial in Alopecia Areata

Concert Pharmaceuticals, Inc. to Report Q2, 2022 Results on Aug 04, 2022

Concert Pharmaceuticals, Inc.(NasdaqGM:CNCE) dropped from Russell Microcap Value Index

Concert Pharmaceuticals, Inc. Announces the Publication of Safety and Efficacy Data from the Randomized, Double-Blind, Placebo-Controlled Dose-Ranging Phase 2 Clinical Trial for CTP-543

Concert Pharmaceuticals, Inc. Reports Positive Topline Results for First CTP-543 Phase 3 Clinical Trial in Alopecia Areata

First quarter 2022 earnings released: US$1.03 loss per share (vs US$0.67 loss in 1Q 2021)

Insufficient new directors

Concert Pharmaceuticals, Inc., Annual General Meeting, Jun 09, 2022

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Concert Pharmaceuticals, Inc. Announces Phase 3 Trials for Moderate to Severe Alopecia Areata

Concert Pharmaceuticals, Inc. to Report Q4, 2021 Results on Mar 03, 2022

Concert Pharmaceuticals, Inc. Announces Not Stand for Re-Election of Ronald W. Barrett as Independent Director

Concert Pharmaceuticals, Inc. Completes Enrollment in THRIVE-AA2 Phase 3 Clinical Trial Evaluating CTP-543 for Alopecia Areata

Third quarter 2021 earnings released: US$0.78 loss per share (vs US$0.60 loss in 3Q 2020)

Second quarter 2021 earnings released: EPS US$0.16 (vs US$0.41 loss in 2Q 2020)

Concert Pharmaceuticals Presents Update on CTP-543 Long-Term Extension Study in Alopecia Areata During 2nd JAK Inhibitors Drug Development Summit

Concert Pharmaceuticals, Inc.(NasdaqGM:CNCE) dropped from Russell 3000E Value Index

Concert Pharmaceuticals Initiates THRIVE-AA2 Phase 3 Clinical Trial Evaluating CTP-543 for Alopecia Areata

First quarter 2021 earnings released: US$0.67 loss per share (vs US$0.70 loss in 1Q 2020)

Concert Pharmaceuticals Reports CTP-543 Phase 3 Program for Alopecia Areata Advancing as Planned to Support NDA Filing in Early 2023

Full year 2020 earnings released: US$2.40 loss per share (vs US$3.29 loss in FY 2019)

Revenue beats expectations

Concert Pharmaceuticals, Inc. Provides Update on Clinical Programs

New 90-day low: €5.70

Concert Pharmaceuticals, Inc. to Report Fiscal Year 2020 Results on Feb 25, 2021

Concert Pharmaceuticals, Inc. Announces Results from CTP-692 Phase 2 Trial in Patients with Schizophrenia

New 90-day low: €5.75

New 90-day high: €10.60

Third quarter 2020 earnings released: US$0.60 loss per share

Revenue in line with expectations

Concert Pharmaceuticals Initiates THRIVE-AA1 Phase 3 Clinical Trial Evaluating CTP-543 for Alopecia Areata

Concert Pharmaceuticals, Inc. to Report Q3, 2020 Results on Nov 05, 2020

New 90-day high: €10.20

New 90-day high: €9.65

Concert Pharmaceuticals, Inc. Completes CTP-692 Phase 2 Trial Enrollment in Patients with Schizophrenia

First half earnings released

Previsiones de crecimiento de beneficios e ingresos

Previsiones de crecimiento futuro de los analistas

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

Descubre empresas en crecimiento